(Q35017744)

5 August 2017

1 reference

title

Malaria vaccines: where are we and where are we going? (English)

1 reference

5 August 2017

0 references

1 reference

Shirley A Moore

1

1 reference

5 August 2017

Emma G E Surgey

series ordinal

2

1 reference

5 August 2017

Anthony M Cadwgan

series ordinal

3

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Lancet Infectious Diseases

5 August 2017

published in

1 reference

5 August 2017

volume

2

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

737-743

1 reference

Current status of malaria and potential for control

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

The pathogenic basis of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

The immunology of malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Immune effector mechanisms in malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

The journey of the malaria parasite in the mosquito: hopes for the new century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

1 reference

7 January 2021

Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Host age as a determinant of naturally acquired immunity to Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

From genomics to vaccines: malaria as a model system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Transmission blocking malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Rationale for the development of an engineered sporozoite malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Current developments in malaria transmission-blocking vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Characterization of a novel gut-specific chitinase gene from the human malaria vector Anopheles gambiae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

The role of TH1 and TH2 cells in a rodent malaria infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Multi-gene vaccination against malaria: A multistage, multi-immune response approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Malaria vaccine development: current status

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Malaria vaccines: are seven antigens better than one?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

A multilateral effort to develop DNA vaccines against falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900451-6

7 January 2021

10.1016/S1473-3099(02)00451-6

Identifiers

DOI

1 reference

5 August 2017

1 reference